

# Konstantin Nikolaev

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9384402/publications.pdf>

Version: 2024-02-01

103  
papers

21,718  
citations

50244

46  
h-index

37183

96  
g-index

112  
all docs

112  
docs citations

112  
times ranked

19082  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Hypoglycemic Therapy on the Prognosis for Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2022, 12, 845.	1.1	0
2	The use of a new semi-quantitative rapid test for procalcitonin in the diagnosis of multisegmental community-acquired pneumonia. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 279-282.	0.2	1
3	Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus. <i>Patologiya Krovoobrashcheniya I Kardiokirurgiya</i> , 2021, 25, 27.	0.5	1
4	Association of cardiovascular biomarkers with myocardial and coronary imaging characteristics in patients having acute myocardial infarction and type 2 diabetes mellitus. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 104-106.	0.3	1
5	Evaluation of Clinical Efficiency of Cardioprotective Therapy in Patients with Acute Myocardial Infarction. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2021, 10, 493-503.	0.3	0
6	Estimation of metformin and other sugar reducing therapy influence on the outcomes in patients with acute coronary syndrome and diabetes mellitus type II. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 39-47.	0.3	2
7	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
8	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. <i>International Journal of Stroke</i> , 2020, 15, 308-317.	2.9	12
9	The Frequency of the Minor Polymorphisms in the <i>CYP2C19</i> and <i>VEGFR-2</i> Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome. <i>Genetic Testing and Molecular Biomarkers</i> , 2020, 24, 338-342.	0.3	6
10	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2020, 75, 448-451.	1.2	6
11	Effects of smoking on the level of sp-a and sp-d surfactant proteins in the blood of patients without bronchopulmonary diseases. <i>Bulletin of Siberian Medicine</i> , 2020, 19, 104-111.	0.1	2
12	PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2484.	0.4	0
13	Association of SP-A and SP-D Surfactant Proteins with the Severity of Community Acquired Pneumonia. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2020, 9, 348-355.	0.3	1
14	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
15	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
16	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	0.6	8
17	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
18	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
20	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
21	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
22	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
23	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. <i>Age and Ageing</i> , 2019, 48, 859-866.	0.7	79
24	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	1.0	45
25	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
26	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
27	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2034.	1.2	0
28	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2780-2782.	1.2	30
29	Stroke prevention in patients from Latin American countries with nonvalvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	0.7	16
30	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
31	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
32	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	2.9	44
33	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
34	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. <i>Acta Cardiologica</i> , 2019, 74, 309-318.	0.3	16
35	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
36	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60

#	ARTICLE	IF	CITATIONS
37	Association between genetic determinants of clopidogrel metabolism and clinical cardiovascular risk indicators in Buryat patients. <i>Patologiya Krovoobrashcheniya I Kardiokhirurgiya</i> , 2019, 23, 39.	0.5	1
38	Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2019, 18, 23-26.	0.4	0
39	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. <i>Journal of Clinical Lipidology</i> , 2018, 12, 958-965.	0.6	44
40	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	1.0	28
41	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199
42	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 364-367.	1.2	35
43	Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49
44	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018, 131, 813-819.e5.	0.6	17
45	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
46	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
47	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan – Insights From GARFIELD-AF. <i>Circulation Journal</i> , 2018, 83, 67-74.	0.7	12
48	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148
49	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
50	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	1.2	171
51	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 27-35.	1.8	15
52	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
53	Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 749-757.	0.7	11
54	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	1.1	80

#	ARTICLE	IF	CITATIONS
55	Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES. <i>Diabetes</i> , 2018, 67, .	0.3	12
56	Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome. <i>Russian Journal of Cardiology</i> , 2018, , 28-32.	0.4	1
57	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 664-671.	2.2	53
58	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
59	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
60	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
61	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	0.8	30
62	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. <i>Journal of the American College of Cardiology</i> , 2017, 69, 153.	1.2	2
63	EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 315.	1.2	0
64	TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 364.	1.2	0
65	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
66	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
67	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
68	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Trial. <i>New England Journal of Medicine</i> , 2017, 185, 93-100.	1.2	48
69	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	1.2	161
70	Associations of psychosocial risk factors and clinical characteristics of acute coronary syndrome in the patients with target values of LDL-C living in the North. <i>Atherosclerosis</i> , 2017, 263, e176.	0.4	0
71	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
72	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40

#	ARTICLE	IF	CITATIONS
73	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61
74	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92
75	CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 107-114.	0.4	14
76	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease—Results From EMPA-REG OUTCOME. <i>Circulation Journal</i> , 2017, 81, 227-234.	0.7	110
77	REGIONAL ASPECTS OF THE GENE POLYMORPHISM VDR-GFR2 WITH CORONARY ATHEROSCLEROSIS IN ACUTE CORONARY SYNDROME. <i>Russian Journal of Cardiology</i> , 2017, , 61-65.	0.4	1
78	THE PROTOCOL: INFLUENCE OF THE COMBINATION CARRIAGE DRUGS 19*2 AND *17 ON EFFICACY OF CLOPIDOGREL. <i>Russian Journal of Cardiology</i> , 2017, , 113-117.	0.4	0
79	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
80	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	1.0	83
81	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	0.7	53
82	Edoxaban versus enoxaparin or warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2016, 388, 1995-2003.	6.3	206
83	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016, 223, 543-547.	0.8	71
84	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	1.3	21
85	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	13.9	2,809
86	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	1.2	13
87	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	13.9	208
88	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	1.2	6
89	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
90	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118

#	ARTICLE	IF	CITATIONS
91	THE INFLUENCE OF PSYCHOSOCIAL FACTORS ON THE DEVELOPMENT OF ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROME. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 58-62.	0.4	5
92	Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. European Heart Journal, 2015, 36, 2510-2519.	1.0	169
93	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AFâ€“TIMI 48 trial. American Heart Journal, 2015, 170, 1140-1150.	1.2	26
94	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499.	13.9	1,838
95	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	0.9	74
96	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	6.3	659
97	Associations of functional and biochemical parameters of endothelial dysfunction in postmenopausal women with a different state of carbohydrate metabolism. Diabetes Mellitus, 2015, 18, 105-112.	0.5	0
98	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	1.0	46
99	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261
100	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	13.9	4,215
101	521 RAPID AND EFFICIENT IMMUNOCHROMATOGRAPHIC FATTY ACID BINDING PROTEIN ASSAY FOR EARLY DIAGNOSIS OF MYOCARDIAL INFARCTION. Atherosclerosis Supplements, 2011, 12, 111.	1.2	0
102	Human chemical status and endothelial function. Journal of Surface Investigation, 2011, 5, 1098-1101.	0.1	1
103	ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DECREASE IN HEART REMODELING AND IMPROVEMENT IN FUNCTION OF ENDOTHELIUM IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology, 2006, 2, 12-17.	0.3	0